Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple-ascending-dose Trial to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of Intravenous PNT001 in Hospitalized Patients With Traumatic Brain Injury (TBI)
Latest Information Update: 01 Jul 2022
At a glance
- Drugs PNT 001 (Primary) ; Glucose
- Indications Traumatic brain injuries
- Focus Adverse reactions
- Sponsors Pinteon Therapeutics
- 23 Jun 2022 Status changed from recruiting to discontinued.
- 04 Oct 2021 Planned End Date changed from 1 Jul 2022 to 1 Jan 2023.
- 04 Oct 2021 Planned primary completion date changed from 1 Jul 2022 to 1 Jan 2023.